PMC:7200337 / 72116-73067 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T648","span":{"begin":643,"end":646},"obj":"Body_part"},{"id":"T649","span":{"begin":828,"end":833},"obj":"Body_part"}],"attributes":[{"id":"A648","pred":"fma_id","subj":"T648","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A649","pred":"fma_id","subj":"T649","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro (Dai et al., 2020). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity in vitro, and one exhibited limited toxicity in vivo (Dai et al., 2020). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 (Yamamoto et al., 2020), and nelfinavir was the most potent at inhibiting viral replication."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T430","span":{"begin":82,"end":90},"obj":"Disease"},{"id":"T431","span":{"begin":189,"end":197},"obj":"Disease"},{"id":"T432","span":{"begin":374,"end":382},"obj":"Disease"},{"id":"T433","span":{"begin":610,"end":618},"obj":"Disease"},{"id":"T434","span":{"begin":848,"end":856},"obj":"Disease"}],"attributes":[{"id":"A430","pred":"mondo_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A431","pred":"mondo_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A432","pred":"mondo_id","subj":"T432","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A433","pred":"mondo_id","subj":"T433","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A434","pred":"mondo_id","subj":"T434","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro (Dai et al., 2020). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity in vitro, and one exhibited limited toxicity in vivo (Dai et al., 2020). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 (Yamamoto et al., 2020), and nelfinavir was the most potent at inhibiting viral replication."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T824","span":{"begin":93,"end":98},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T825","span":{"begin":411,"end":412},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T826","span":{"begin":457,"end":465},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T827","span":{"begin":811,"end":819},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T828","span":{"begin":823,"end":827},"obj":"http://purl.obolibrary.org/obo/CLO_0009524"},{"id":"T829","span":{"begin":823,"end":827},"obj":"http://purl.obolibrary.org/obo/CLO_0050515"},{"id":"T830","span":{"begin":828,"end":833},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro (Dai et al., 2020). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity in vitro, and one exhibited limited toxicity in vivo (Dai et al., 2020). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 (Yamamoto et al., 2020), and nelfinavir was the most potent at inhibiting viral replication."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T136","span":{"begin":12,"end":21},"obj":"Chemical"},{"id":"T1987","span":{"begin":159,"end":163},"obj":"Chemical"},{"id":"T138","span":{"begin":347,"end":357},"obj":"Chemical"},{"id":"T23982","span":{"begin":580,"end":599},"obj":"Chemical"},{"id":"T79279","span":{"begin":589,"end":599},"obj":"Chemical"},{"id":"T142","span":{"begin":643,"end":666},"obj":"Chemical"},{"id":"T47039","span":{"begin":647,"end":666},"obj":"Chemical"},{"id":"T57695","span":{"begin":656,"end":666},"obj":"Chemical"},{"id":"T146","span":{"begin":668,"end":678},"obj":"Chemical"},{"id":"T62961","span":{"begin":680,"end":689},"obj":"Chemical"},{"id":"T148","span":{"begin":691,"end":700},"obj":"Chemical"},{"id":"T64327","span":{"begin":702,"end":712},"obj":"Chemical"},{"id":"T150","span":{"begin":714,"end":724},"obj":"Chemical"},{"id":"T67444","span":{"begin":726,"end":736},"obj":"Chemical"},{"id":"T152","span":{"begin":738,"end":748},"obj":"Chemical"},{"id":"T23276","span":{"begin":750,"end":759},"obj":"Chemical"},{"id":"T12434","span":{"begin":765,"end":774},"obj":"Chemical"},{"id":"T52451","span":{"begin":801,"end":810},"obj":"Chemical"},{"id":"T96509","span":{"begin":888,"end":898},"obj":"Chemical"}],"attributes":[{"id":"A9096","pred":"chebi_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A49893","pred":"chebi_id","subj":"T1987","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A32728","pred":"chebi_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A9528","pred":"chebi_id","subj":"T23982","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A58721","pred":"chebi_id","subj":"T23982","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A50749","pred":"chebi_id","subj":"T79279","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A95910","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_35660"},{"id":"A96279","pred":"chebi_id","subj":"T47039","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A48242","pred":"chebi_id","subj":"T47039","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A62320","pred":"chebi_id","subj":"T57695","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A8787","pred":"chebi_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/CHEBI_7496"},{"id":"A16605","pred":"chebi_id","subj":"T62961","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A98163","pred":"chebi_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A78781","pred":"chebi_id","subj":"T64327","obj":"http://purl.obolibrary.org/obo/CHEBI_63621"},{"id":"A40785","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_37924"},{"id":"A1647","pred":"chebi_id","subj":"T67444","obj":"http://purl.obolibrary.org/obo/CHEBI_63628"},{"id":"A74397","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_40050"},{"id":"A13828","pred":"chebi_id","subj":"T23276","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A68640","pred":"chebi_id","subj":"T12434","obj":"http://purl.obolibrary.org/obo/CHEBI_44032"},{"id":"A8143","pred":"chebi_id","subj":"T52451","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A91235","pred":"chebi_id","subj":"T96509","obj":"http://purl.obolibrary.org/obo/CHEBI_7496"}],"text":"Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro (Dai et al., 2020). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity in vitro, and one exhibited limited toxicity in vivo (Dai et al., 2020). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 (Yamamoto et al., 2020), and nelfinavir was the most potent at inhibiting viral replication."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T182","span":{"begin":922,"end":950},"obj":"http://purl.obolibrary.org/obo/GO_1903901"},{"id":"T183","span":{"begin":933,"end":950},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T184","span":{"begin":933,"end":950},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro (Dai et al., 2020). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity in vitro, and one exhibited limited toxicity in vivo (Dai et al., 2020). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 (Yamamoto et al., 2020), and nelfinavir was the most potent at inhibiting viral replication."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2313","span":{"begin":138,"end":142},"obj":"Gene"},{"id":"2314","span":{"begin":280,"end":284},"obj":"Gene"},{"id":"2315","span":{"begin":600,"end":602},"obj":"Gene"},{"id":"2316","span":{"begin":567,"end":569},"obj":"Gene"},{"id":"2317","span":{"begin":385,"end":389},"obj":"Gene"},{"id":"2318","span":{"begin":200,"end":204},"obj":"Gene"},{"id":"2319","span":{"begin":82,"end":92},"obj":"Species"},{"id":"2320","span":{"begin":189,"end":199},"obj":"Species"},{"id":"2321","span":{"begin":374,"end":384},"obj":"Species"},{"id":"2322","span":{"begin":610,"end":620},"obj":"Species"},{"id":"2323","span":{"begin":848,"end":858},"obj":"Species"},{"id":"2324","span":{"begin":668,"end":678},"obj":"Chemical"},{"id":"2325","span":{"begin":680,"end":689},"obj":"Chemical"},{"id":"2326","span":{"begin":691,"end":700},"obj":"Chemical"},{"id":"2327","span":{"begin":702,"end":712},"obj":"Chemical"},{"id":"2328","span":{"begin":714,"end":724},"obj":"Chemical"},{"id":"2329","span":{"begin":726,"end":736},"obj":"Chemical"},{"id":"2330","span":{"begin":738,"end":748},"obj":"Chemical"},{"id":"2331","span":{"begin":750,"end":759},"obj":"Chemical"},{"id":"2332","span":{"begin":765,"end":774},"obj":"Chemical"},{"id":"2333","span":{"begin":888,"end":898},"obj":"Chemical"},{"id":"2334","span":{"begin":502,"end":510},"obj":"Disease"},{"id":"2335","span":{"begin":834,"end":842},"obj":"Disease"}],"attributes":[{"id":"A2313","pred":"tao:has_database_id","subj":"2313","obj":"Gene:8673700"},{"id":"A2314","pred":"tao:has_database_id","subj":"2314","obj":"Gene:8673700"},{"id":"A2315","pred":"tao:has_database_id","subj":"2315","obj":"Gene:6999"},{"id":"A2316","pred":"tao:has_database_id","subj":"2316","obj":"Gene:6999"},{"id":"A2317","pred":"tao:has_database_id","subj":"2317","obj":"Gene:8673700"},{"id":"A2318","pred":"tao:has_database_id","subj":"2318","obj":"Gene:8673700"},{"id":"A2319","pred":"tao:has_database_id","subj":"2319","obj":"Tax:2697049"},{"id":"A2320","pred":"tao:has_database_id","subj":"2320","obj":"Tax:2697049"},{"id":"A2321","pred":"tao:has_database_id","subj":"2321","obj":"Tax:2697049"},{"id":"A2322","pred":"tao:has_database_id","subj":"2322","obj":"Tax:2697049"},{"id":"A2323","pred":"tao:has_database_id","subj":"2323","obj":"Tax:2697049"},{"id":"A2324","pred":"tao:has_database_id","subj":"2324","obj":"MESH:D019888"},{"id":"A2325","pred":"tao:has_database_id","subj":"2325","obj":"MESH:D061466"},{"id":"A2326","pred":"tao:has_database_id","subj":"2326","obj":"MESH:D019438"},{"id":"A2327","pred":"tao:has_database_id","subj":"2327","obj":"MESH:D019258"},{"id":"A2328","pred":"tao:has_database_id","subj":"2328","obj":"MESH:D000069446"},{"id":"A2329","pred":"tao:has_database_id","subj":"2329","obj":"MESH:C107201"},{"id":"A2330","pred":"tao:has_database_id","subj":"2330","obj":"MESH:C095108"},{"id":"A2331","pred":"tao:has_database_id","subj":"2331","obj":"MESH:D000069454"},{"id":"A2332","pred":"tao:has_database_id","subj":"2332","obj":"MESH:D019469"},{"id":"A2333","pred":"tao:has_database_id","subj":"2333","obj":"MESH:D019888"},{"id":"A2334","pred":"tao:has_database_id","subj":"2334","obj":"MESH:D064420"},{"id":"A2335","pred":"tao:has_database_id","subj":"2335","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro (Dai et al., 2020). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity in vitro, and one exhibited limited toxicity in vivo (Dai et al., 2020). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 (Yamamoto et al., 2020), and nelfinavir was the most potent at inhibiting viral replication."}

{"project":"LitCovid-sentences","denotations":[{"id":"T403","span":{"begin":0,"end":144},"obj":"Sentence"},{"id":"T404","span":{"begin":145,"end":304},"obj":"Sentence"},{"id":"T405","span":{"begin":305,"end":413},"obj":"Sentence"},{"id":"T406","span":{"begin":414,"end":538},"obj":"Sentence"},{"id":"T407","span":{"begin":539,"end":628},"obj":"Sentence"},{"id":"T408","span":{"begin":629,"end":951},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Much of the antiviral computational and experimental data currently available for SARS-CoV-2 focus on targeting the 3CL or Main protease (Mpro). Two prominent drug candidates targeting the SARS-CoV-2 Mpro were designed and synthesized by analyzing the substrate binding pocket of Mpro (Dai et al., 2020). The X-ray crystal structures of the novel inhibitors in complex with SARS-CoV-2 Mpro were resolved at 1.5 Å. Both compounds showed good pharmacokinetic activity in vitro, and one exhibited limited toxicity in vivo (Dai et al., 2020). Multiple studies also aimed to repurpose protease inhibitors to reduce SARS-CoV-2 titers. Nine existing HIV protease inhibitors (nelfinavir, lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir) were evaluated for their antiviral activity in Vero cells infected with SARS-CoV-2 (Yamamoto et al., 2020), and nelfinavir was the most potent at inhibiting viral replication."}